The effects of amla on low-density lipoprotein (LDL) oxidation and cholesterol levels were investigated in vitro and in vivo using Cuetinduced LDL oxidation and choles terol-fed rats. SunAmla and ethyl acetate (EtOAc) extract of amla significantly inhibited thiobarbituric acid (TBA)-reactive substance level in the Cu2+-induced LDL oxidation and the effects were stronger than those of probucol. In addition, the administration of SunAmla (at a dose of 20 or 40mg/kg body weight/d) or EtOAc extract of amla (at a dose of 10 or 20mg/kg body weight/d) for 20 d to rats fed 1% cholesterol diet significantly reduced total, free and LDL-cholesterol levels in a dose-dependent manner, and EtOAc extract of amla exhibited more potent serum cholesterol-lowering effect than SunAmla in the same amount. Furthermore, the oxidized LDL level in serum was markedly elevated in choles terol-fed control rats as compared with normal rats, while it was significantly decreased by the administration of SunAmla or EtOAc extract of amla. Moreover, the serum TBA-reactive substance level was also significantly decreased after oral administration of SunAmla or EtOAc extract of amla. These results suggest that amla may be effective for hypercholester olemia and prevention of atherosclerosis.
Coronary artery disease (CAD), a major cause of morbidity and mortality worldwide, develops as a result of various risk factors including hypercholesterolemia, diabetes, hypertension, smoking, aging, and nitrate intolerance (1) . Many studies have shown that in creased cholesterol concentration in plasma is a cause of coronary atherosclerosis and increase risk of CAD (2 5) . In addition, it is widely understood that low-density lipoprotein (LDL)-cholesterol and LDL modification, such as oxidation and aggregation, play an important role in the pathogenesis of atherosclerotic conditions (3, 6) . Oxidative modification of LDL is causally involved in the initiation and promotion of atherosclerosis (7) . In vitro and in vivo studies have suggested that atheroge nicity of LDL was greatly enhanced by oxidative dam age. Moreover, in animal experiments, LDL of hypercho lesterolemic rabbits was more susceptible to oxidative modification than that of normolipidemic rabbits (8) . Thus, an increased cholesterol level can be a significant predictor of the development of CAD. Recently, several studies have indicated that diet treatment or drug ther apy that lowers LDL cholesterol levels can reduce subse quent CAD-associated morbidity and mortality (6, 9) . In particular, much attention has been focused on the possible use of antioxidant agents to inhibit the oxida tion of LDL for preventing atherosclerosis.
The Emblica officinalis Gaertn, commonly known as amla, is a member of the small genus Emblica (Euphor biaceae). It grows in tropical and subtropical parts of China, India, Indonesia and the Malay Peninsula. It is an important dietary source of vitamin C, minerals and amino acids and also contains phenolic compounds, tannins, phyllembelic acid, phyllemblin, rutin, cur cuminoides and emblicol. All parts of the plant are used for medicinal purposes. The fruit especially has been used in Ayurveda as a potent rasayana (10) and in tra ditional medicines for the treatment of diarrhea, jaun dice and inflammations (11) . In addition, the pulp of the fruit is smeared on the head to dispel headache and dizziness (12) . Recently, amla extract has been tested for various pharmacological activities. The fruit extract was reported to have hypolipidemic (13) , antidiabetic (14) , and antiinflammatory activity (15) and to inhibit retroviruses such as HIV-1 (16), tumor development (17) and gastric ulcer (18) . Moreover, amla extract exhibits antioxidant properties (19, 20) and it has been reported that the aqueous extract of amla is a potent inhibitor of lipid peroxide formation and a scavenger of hydroxyl and superoxide radicals in vitro (21) . On the basis of these studies, amla would be expected to show activities against LDL oxidation and hypercholester olemia.
In the present study, we investigated the effects of In vitro LDL oxidation Values are presented as mean. Body and liver weights Table 3 shows the effect of amla on the changes in body and liver weights. There were no differences in body weight gain among the groups. The liver weight in rats fed a high cholesterol diet was slightly increased as compared with that in normal rats, but the administra tion of SunAmla or EtOAc extract of amla did not result in a difference from the liver weights of the control rats fed a high-cholesterol diet.
Serum cholesterol levels Table 5 represents the effect of amla on serum oxi dized LDL in cholesterol-fed rats. As compared to nor mal rats, the oxidized LDL level was markedly elevated in cholesterol-fed rats. The oral administration of Sun Amla or EtOAc extract of amla, however, effectively reduced the oxidized LDL level. The oxidized LDL value of the cholesterol-fed control group was 35.2 nmol MDA/mg protein. However, the oxidized LDL level was significantly lower by 68% from that of the cholesterol fed control group after the administration of SunAmla at a dose of 40mg/kg body weight/d and by 45% after the administration of EtOAc extract of amla at 10mg/ kg body weight/d. TBA-reactive substance formation Table 6 shows the effect of amla on lipid peroxidation in cholesterol-fed rats. The serum TBA-reactive sub stance level was maintained at 3.24 nmol/mg protein in cholesterol-fed rats, but the oral administration of SunAmla or EtOAc extract of amla significantly inhib ited the formation of a TBA-reactive substance level in a dose-dependent manner.
DISCUSSION
The epidemiologic and intervention studies show that high intake of an antioxidant such as phenolic compounds, mainly derived from plant sources, is effec tive in reducing the risk of CAD, and it has been observed experimentally that supplementation with antioxidants can attenuate atherosclerosis in animal models (27) (28) (29) (30) . Furthermore, the use of traditional medicines or a crude drug has had a major part in the management of many chronic disease, and it has been explored or assessed for efficacy on the inhibition of LDL oxidation and also the development of atherosclerosis. Therefore, we evaluated the antioxidant activity of amla using Cue-induced human LDL oxidation. This study showed that amla inhibited the LDL peroxidation induced by Cu2+ ( Table 2 ), suggesting that amla would protect against LDL peroxidation in vivo by playing a role as an antioxidant.
In our present study, the cholesterol-fed rats showed high levels of total and free cholesterol in serum as com pared with normal rats, but oral administration of amla reduced the high levels of cholesterol. In addition, the serum LDL-cholesterol-level was significantly reduced by amla (Table 4) . When there is excess LDL in the blood, it is deposited in the blood vessel walls and becomes a major component of atherosclerotic plaque lesions. Therefore, serum LDL-cholesterol level should be used as the basis for initiating and monitoring treat ment of patients with elevated blood cholesterol (31, 32) . Ross (1) demonstrated that experimental animals which consumed high dietary levels of cholesterol developed elevated LDL-cholesterol levels and athero sclerosis and suggested the pathological process could be reversed by reducing the serum LDL-cholesterol lev els. Our results indicate that amla would be a potential therapeutic agent for atherosclerosis through lowering serum levels of cholesterol.
The lowering mechanism of the cholesterol level in serum is thought to decrease de novo synthesis of cho lesterol through inhibition of 3-hydroxy-3-methylglu taryl coenzyme A (HMG-CoA) reductase, the rate-limit ing enzyme in cholesterol synthesis, affecting lipo protein metabolism and reducing absorption of choles terol (33) . Therefore, the lowering effect of serum cho lesterol by amla may be associated with interference with the synthesis as well as secretion of lipoprotein into plasma and/or with acceleration of the removal of the circulating cholesterol for excretion. It is also specu lated that the elevated fecal bile acid excretion lowered the reabsorption of bile acid by the enterohepatic circu lation and a simultaneous inhibition of HMG-CoA reductase resulted in a lower plasma cholesterol con centration (33) . However, the mechanism of the choles terol-lowering activity of amla remains to be elucidated.
Hypercholesterolemic atherosclerosis is associated with an increase in the level of the lipid peroxidation product malondialdehyde, which is an index of the level of oxygen free radicals (34, 35) . A decrease in lipid per oxidation leads to a reduction in arterial wall choles terol content. Oxidized LDL is incorporated by macro phages via scavenger receptors, resulting in the forma tion of foam cells containing large amounts of choles terol ester (36) . Therefore, the reduction of atheroscle rosis caused by hypercholesterolemia may be associated with a decrease in lipid peroxidation, including inhibi tion of the LDL oxidation. In addition, Gugliucci et al. (37) and Cestaro et al. (38) reported that the lipid per oxidation of plasma mainly represents the LDL oxida tion, and the whole plasma oxidation is used to evaluate the relative roles of the different endogenous antioxi dants. Kim et al. (39) reported that a traditional Korean prescription Geiji-Bokryung-Hwan and probucol reduced plasma cholesterol levels in the rabbits. This study con cludes that the reduction in atherosclerosis by Geiji Bokryung-Hwan relies not only on its cholesterol-low ering effect but also more heavily on its antioxidant potential, which prevents endothelial damage and inhibits LDL oxidative modification in hypercholester olemic animals. In this study, we measured the serum TBA-reactive substance level in cholesterol-fed rats, and the TBA-reactive substance level was significantly decreased after administration of amla (Table 6 ). These findings imply that amla would protect against the development of hypercholesterolemic atherosclerosis by decreasing lipid peroxidation.
Polyphenolic flavonoids may prevent CAD by reduc ing plasma cholesterol levels and by inhibiting LDL oxi dation, a process which is thought to play a key role in the pathogenesis of atherosclerosis (40) . We have previ ously reported that the plant food-derived ingredient, polyphenol, also acts as a hypocholesterolemic agent and has an inhibitory effect on oxidized LDL (41) . In our present study, EtOAc extract of amla, a flavonoid rich fraction, exhibited stronger protective activities on LDL oxidation and hypercholesterolemia than Sun Amla. These results also support the findings that fla vonoids from amla reduced lipid level in serum and tis sue of rats with induced hyperlipidemia (13) .
In summary, the present study showed that amla inhibited the oxidation of LDL in vitro and in vivo and administration of amla to cholesterol-fed rats signifi cantly reduced serum cholesterol levels. From these results, we suggest that amla would be effective in pre venting hypercholesterolemic atherosclerosis and low ering the relative risk of CAD through decreases in lipid peroxidation and cholesterol levels.
